Zacks: Immunic (NASDAQ:IMUX) Given Average Rating of “Strong Buy” by Brokerages
Immunic (NASDAQ:IMUX) has earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $44.75 for the company and are forecasting that the company will post ($0.80) earnings per share for the current quarter, according to Zacks. Zacks has also given Immunic an industry rank of 16 out of 254 based on the ratings given to related companies.
A number of research firms have recently weighed in on IMUX. ValuEngine lowered Immunic from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 11th. HC Wainwright started coverage on Immunic in a research note on Monday, May 11th. They issued a “buy” rating and a $45.00 price target for the company. Roth Capital started coverage on Immunic in a report on Wednesday, March 25th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Zacks Investment Research downgraded Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, March 25th.
NASDAQ IMUX traded up $0.19 during trading on Monday, hitting $10.12. 193,400 shares of the company’s stock traded hands, compared to its average volume of 113,100. The business has a 50 day moving average of $8.53 and a 200-day moving average of $8.12. Immunic has a 12-month low of $4.19 and a 12-month high of $19.05. The stock has a market capitalization of $129.44 million, a price-to-earnings ratio of -2.74 and a beta of 3.05.
Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.79) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.17. On average, research analysts expect that Immunic will post -2.93 earnings per share for the current fiscal year.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Read More: What does a market perform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.